170 related articles for article (PubMed ID: 35600346)
1. Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma.
Dieckmann KP; Klemke M; Grobelny F; Radtke A; Dralle-Filiz I; Wülfing C; Belge G
Front Oncol; 2022; 12():889624. PubMed ID: 35600346
[TBL] [Abstract][Full Text] [Related]
2. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
3. Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.
Dieckmann KP; Dumlupinar C; Grobelny F; Utschig J; Klemke M; Ahmed Saad EM; Wülfing C; Pichlmeier U; Isbarn H; Belge G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7079-7090. PubMed ID: 36869885
[TBL] [Abstract][Full Text] [Related]
4. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G; Dumlupinar C; Nestler T; Klemke M; Törzsök P; Trenti E; Pichler R; Loidl W; Che Y; Hiester A; Matthies C; Pichler M; Paffenholz P; Kluth L; Wenzel M; Sommer J; Heinzelbecker J; Schriefer P; Winter A; Zengerling F; Kramer MW; Lengert M; Frey J; Heidenreich A; Wülfing C; Radtke A; Dieckmann KP
Clin Cancer Res; 2024 Jan; 30(2):404-412. PubMed ID: 37967143
[TBL] [Abstract][Full Text] [Related]
5. Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.
Dieckmann KP; Dumlupinar C; Radtke A; Matthies C; Pichler R; Paffenholz P; Sommer J; Winter A; Zengerling F; Hennig F; Wülfing C; Belge G
World J Urol; 2022 Feb; 40(2):317-326. PubMed ID: 34775512
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.
Belge G; Grobelny F; Radtke A; Bodes J; Matthies C; Wülfing C; Dieckmann KP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):435-443. PubMed ID: 33200255
[TBL] [Abstract][Full Text] [Related]
7. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
8. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
9. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
Radtke A; Hennig F; Ikogho R; Hammel J; Anheuser P; Wülfing C; Belge G; Dieckmann KP
Urol Int; 2018; 100(4):470-475. PubMed ID: 29698973
[TBL] [Abstract][Full Text] [Related]
10. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma.
Warren GP; Einhorn LH
J Clin Oncol; 1995 Nov; 13(11):2784-8. PubMed ID: 7595739
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.
Duchesne GM; Stenning SP; Aass N; Mead GM; Fosså SD; Oliver RT; Horwich A; Read G; Roberts IT; Rustin G; Cullen MH; Kaye SB; Harland SJ; Cook PA
Eur J Cancer; 1997 May; 33(6):829-35. PubMed ID: 9291801
[TBL] [Abstract][Full Text] [Related]
13. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
15. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
16. The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern.
Ernst S; Heinzelmann J; Bohle RM; Weber G; Stöckle M; Junker K; Heinzelbecker J
Andrology; 2020 Nov; 8(6):1687-1698. PubMed ID: 32530514
[TBL] [Abstract][Full Text] [Related]
17. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
19. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
20. The management of residual masses after chemotherapy in metastatic seminoma.
Ravi R; Ong J; Oliver RT; Badenoch DF; Fowler CG; Hendry WF
BJU Int; 1999 Apr; 83(6):649-53. PubMed ID: 10233573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
